Peptide Knowledge Base · GH-axis

Sermorelin: what it is, what the evidence says, and its real status

A GHRH analog that nudges your own growth-hormone rhythm for recovery, muscle, and sleep.

Can you actually get it?

Plain-English verdict: Available.

Regulatory status: 503A interim Category 1 (enforcement discretion, not the 503A Bulks List).

How does Sermorelin work?

Sermorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH 1–29). It signals the pituitary to produce and release the body's own growth hormone, rather than introducing growth hormone directly.

What it does — and what it does not do

What it does: Used to support muscle, recovery, and sleep quality.

What it does not do: It is not anabolic steroid therapy and is not a guaranteed performance enhancer.

How honest is the evidence?

Evidence grade C — Mixed / early human evidence.

moderate clinical history as a GHRH analog; outcome data is limited

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term outcome data is limited; effects vary with age and baseline.

WADA status: Banned (S2).

How it is taken

Clinician-set; typically evening subcutaneous.

Who should not take it

Banned in tested sport (WADA S2). Discuss active malignancy and pituitary history with a clinician.

Sources

Walker, sermorelin / GHRH-analog clinical reviews · FDA labeling history (Geref)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.